B+
Bull case
25%
Probability
Target price
$133.00
+15.2% vs current
ADUS
Addus HomeCareBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-08-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$115.00
-0.4% vs current
B-
Bear case
25%
Probability
Target price
$101.00
-12.5% vs current
AI sentiment snapshot
Latest data as of 2026-07-24
Recent news sentiment (30D)
+28.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
+28.0
Positive
Sentiment proxy
+47.2
Score
AI commentary
News flow is moderately active around Q1 results and the upcoming Q2 reporting cycle, but the available earnings recap was secondary and revision data is unavailable. The primary SEC 8-K confirms that Addus reported Q1 results on May 4, 2026 [#SEC-8K-2026-05-04]. Overall sentiment is mildly positive, with insufficient forward evidence for a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-07-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-22eventQ2 2026 earnings release and conference callMedium impact
A July 20 company earnings announcement is listed in the packet, but the exact release and call date is not provided. Results, guidance, labor costs, reimbursement trends, and service volumes are the next material validation points.
2026-10-22catalystPost-Q1 earnings digestionMedium impact
Stored earnings context reports Q1 revenue of $363.6 million, up 7.7% year over year but 0.7% below expectations; the shares were nevertheless reported higher after the print. The signal is constructive but not decisive.
2027-07-24catalystNew York personal-care divestiture executionMedium impact
The 2026 10-Q states that uncertainty around New York CDPAP led the company to conclude that its New York personal-care operations no longer fit its growth strategy and that it is divesting them [#SEC-10Q-2026-05-05]. Successful execution could improve strategic focus, but proceeds, transition costs, and operating impact remain unclear.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-24 • Updated nightlySource: Internal modelMethodology